Benzinga | Sep 30, 2021 07:23AM EDT

Eli Lilly Shares Positive Tirzepatide Data At EASD Annual Meeting

* Eli Lilly And Co (NYSE: LLY) posted data from the SURPASS-3 CGM sub-study of tirzepatide in a subpopulation of 243 participants who wore continuous glucose monitoring (CGM) for 7 to 10 days at baseline.

* Related Link: Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study.

* All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability, and numerically less time in hypoglycemia than titrated insulin degludec in adults with type 2 diabetes.

* Specifically, at 52 weeks, participants taking tirzepatide spent 72.6% of the 24 hours in tight target range (71-140 mg/dL) for pooled 10 mg and 15 mg arms, an average of approximately six more hours than those taking insulin degludec (48.0%).

* Lilly also shared data MRI sub-study showing that tirzepatide led to greater improvements in liver fat content (LFC) and abdominal adipose tissue than titrated insulin degludec in adults with type 2 diabetes.

* Participants taking tirzepatide at 52 weeks showed a greater absolute reduction from baseline in LFC for pooled 10 mg and 15 mg arms (-8.09% from 15.67% at baseline) than insulin degludec (-3.38% from 16.58% at baseline), the primary endpoint.

* Also, a greater relative reduction from baseline in LFC (29.78%-47.11% across the three doses) compared to 11.17% for insulin degludec.

* The data were presented at the 57th European Association for the Study of Diabetes Annual Meeting.

* Also Read: Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients.

* Price Action: LLY stock traded 0.16% higher at $230.72 premarket on the last check Thursday.